查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1600159

分子診斷市場：按技術、產品、應用和最終用戶分類 - 全球預測 2025-2030

Molecular Diagnostics Market by Technology (Chips and Microarrays, In Situ Hybridization, Mass Spectrometry (MS)), Product (Instruments, Reagents), Application, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年分子診斷市值為315.9億美元，預計2024年將達到363億美元，複合年成長率為15.82%，預計到2030年將達到883.6億美元。

分子診斷的範圍包括使用分子生物學技術分析遺傳物質和蛋白質來診斷和監測疾病、評估特定疾病的風險並確定預後的廣泛測試。作為個人化醫療的重要工具，它的需求在於其準確性和提供早期準確診斷並實現客製化治療策略的能力。分子診斷應用於感染疾病檢測、腫瘤學、基因檢測和藥物基因組學，並交付給醫院、實驗室、研究機構和製藥公司等最終用戶。該市場受到感染疾病和癌症的增加、分子診斷技術的技術進步以及對個人化醫療日益成長的興趣的影響。

主要市場統計
基準年[2023] 315.9億美元
預測年份 [2024] 363億美元
預測年份 [2030] 883.6億美元
複合年成長率（%） 15.82%

最近出現的機會是將人工智慧和機器學習整合到診斷平台中，以增強資料分析和預測能力。為應對這場流行病而建立的檢測開發策略聯盟和增加政府資金也指出了成長的途徑。然而，高測試成本、嚴格的監管核准以及對先進基礎設施的需求等限制因素可能會限制採用，特別是在資源匱乏的環境中。開拓標準化通訊協定和改善新興市場的准入是應對這些挑戰的重要步驟。

具有創新潛力的領域包括就地檢驗、具有成本效益的定序技術以及導致新診斷測試的生物標記發現。生物技術公司和醫療保健提供者之間的夥伴關係可以加速這些創新的開發和實施。分子診斷市場本質上是動態的，受到快速技術發展和醫療保健領域轉向以診斷為中心的方法的推動。公司可以透過專注於擴大其檢測產品組合以納入罕見疾病並利用數位健康技術來最佳化工作流程和改善患者治療結果來建立戰略地位。繼續適應快速發展的科學進步和監管環境是維持該領域業務成長的關鍵。

市場動態：揭示快速發展的分子診斷市場的關鍵市場洞察

供需的動態交互作用正在改變分子診斷市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 感染疾病及各種癌症盛行率高 醫院感染盛行率
    • 政府津貼增加
    • 照護現場的需求增加
  • 市場限制因素
    • 缺乏清晰統一的法律規範
    • 訓練有素的專業人員效率低下限制了新分子診斷技術的適當使用
  • 市場機會
    • 分子診斷技術的進步和疾病早期診斷意識的提高
    • 活性化新興國家的研發活動
  • 市場問題
    • 新分子診斷測試的核准延遲
    • 核准流程嚴格規定

波特五力：駕馭分子診斷市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架描述了評估公司競爭和探索策略機會的清晰方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解分子診斷市場的外部影響

外部宏觀環境因素在塑造分子診斷市場的績效動態發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析：了解分子診斷市場的競爭格局

對分子診斷市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、細分和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣：分子診斷市場供應商績效評估

FPNV定位矩陣是評估分子診斷市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議：繪製分子診斷市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，分子診斷市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

該報告對涵蓋關鍵焦點細分市場的市場進行了全面分析。

1.市場滲透率：對當前市場環境的詳細審查，主要企業的廣泛資料，評估他們在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有細分市場的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策。

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品和地區提供最佳投資機會？

3.塑造市場的關鍵技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 感染疾病和各種癌症盛行率高，醫院感染盛行率高
      • 政府資助增加
      • 照護現場的需求增加
    • 抑制因素
      • 缺乏清晰統一的法規結構
      • 訓練有素的專業人員效率低下限制了新分子診斷技術的適當使用
    • 機會
      • 分子診斷技術的進步和疾病早期診斷意識的提高
      • 新興國家研發活動增加
    • 任務
      • 新分子診斷測試的核准延遲
      • 嚴格的核准流程規定
  • 市場區隔分析
    • 技術：擴大次世代定序在個人化醫療和標靶治療的應用
    • 應用：將分子診斷整合到精準醫學中，用於感染疾病的早期療育
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

第6章分子診斷市場：依技術分類

  • 介紹
  • 晶片和微陣列
  • 原位雜合反應
  • 質譜（MS）
  • PCR
  • 定序

第7章分子診斷市場：依產品

  • 介紹
  • 裝置
  • 試劑

第8章分子診斷市場：依應用分類

  • 介紹
  • 驗血
  • 遺傳疾病篩檢
  • 人類白血球抗原分型
  • 感染疾病
  • 微生物學
  • 腫瘤學
  • 藥物基因組學

第9章分子診斷市場：依最終用戶分類

  • 介紹
  • 醫院
  • 研究所

第10章美洲分子診斷市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太分子診斷市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲分子診斷市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Guardant Health 推出 Guardant360 TissueNext 測試，包含近 500 個生物標記
    • QIAGEN 和 Myriad Genetics 合作開發全球使用的同源重組缺陷測試
    • Labcorp 推出針對早期大腸直腸癌的臨床檢驗ctDNA 解決方案
  • 戰略分析和建議

公司名單

  • Abbott Laboratories
  • ADT BIoTech
  • Agilent Technologies Inc.
  • Becton, Dickinson, and Company
  • Bio-Rad Laboratories, Inc.
  • Biocartis Group NV
  • bioMerieux SA
  • Danaher Corporation
  • DiaSorin SpA
  • Grifols SA
  • Hologic Inc.
  • Illumina, Inc.
  • Johnson & Johnson
  • LabCorp
  • Myriad Genetics, Inc.
  • Novartis AG
  • Roche Diagnostics Corporation
  • Siemens Healthineers
  • Sysmex Corporation by Oxford Gene Technology
  • Thermo Fisher Scientific Inc.
Product Code: MRR-434CCDA04D46

The Molecular Diagnostics Market was valued at USD 31.59 billion in 2023, expected to reach USD 36.30 billion in 2024, and is projected to grow at a CAGR of 15.82%, to USD 88.36 billion by 2030.

The scope of molecular diagnostics encompasses a wide range of tests that utilize molecular biology techniques to analyze genetic material and proteins to diagnose and monitor diseases, assess the risk of developing certain conditions, and determine prognosis. As a crucial tool in personalized medicine, its necessity lies in its precision and ability to provide early and accurate diagnosis, enabling tailored therapeutic strategies. Molecular diagnostics find applications in infectious disease detection, oncology, genetic testing, and pharmacogenomics, catering to end-users such as hospitals, laboratories, research institutions, and pharmaceutical companies. The market is influenced by increasing incidences of infectious diseases and cancer, technological advancements in molecular diagnostic techniques, and a growing focus on personalized medicine.

KEY MARKET STATISTICS
Base Year [2023] USD 31.59 billion
Estimated Year [2024] USD 36.30 billion
Forecast Year [2030] USD 88.36 billion
CAGR (%) 15.82%

Recent opportunities emerge from the integration of artificial intelligence and machine learning with diagnostic platforms, enhancing data analysis and predictive capabilities. Strategic collaborations for assay development and increased government funding in pandemic preparedness also present growth avenues. However, the market faces limitations due to high costs of tests, stringent regulatory approvals, and the need for sophisticated infrastructure, which can restrict adoption particularly in low-resource settings. Developing standardized protocols and improving access in emerging markets are crucial steps to addressing these challenges.

Innovation areas with potential include point-of-care testing solutions, cost-effective sequencing technologies, and biomarker discovery that can lead to novel diagnostic tests. Partnerships between biotech firms and healthcare providers can expedite the development and implementation of these innovations. The molecular diagnostics market is intrinsically dynamic, driven by rapid technological evolution and a shift towards a more diagnostic-centric approach in healthcare. Businesses can strategically position themselves by focusing on expanding their assay portfolios to include rare diseases and by leveraging digital health technologies to optimize workflows and improve patient outcomes. Remaining adaptable to burgeoning scientific advancements and regulatory landscapes will be key to sustaining business growth in this field.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Molecular Diagnostics Market

The Molecular Diagnostics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • High prevalence of infectious diseases and various types of cancers prevalence rate of hospital-acquired infections
    • Escalation in government funding
    • Increasing demand for point of care diagnostics
  • Market Restraints
    • Lack of clear and uniform regulatory framework
    • Inefficiency of trained professionals limiting the appropriate use of new molecular diagnostic technologies
  • Market Opportunities
    • Technological advancements in molecular diagnostics along with increasing awareness towards early disease diagnosis
    • Rising number of R&D activities in the emerging economies
  • Market Challenges
    • Delay in the approval of new molecular diagnostic tests
    • Stringent regulations associated with the approval process

Porter's Five Forces: A Strategic Tool for Navigating the Molecular Diagnostics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Molecular Diagnostics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Molecular Diagnostics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Molecular Diagnostics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Molecular Diagnostics Market

A detailed market share analysis in the Molecular Diagnostics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Molecular Diagnostics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Molecular Diagnostics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Molecular Diagnostics Market

A strategic analysis of the Molecular Diagnostics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Molecular Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, ADT Biotech, Agilent Technologies Inc., Becton, Dickinson, and Company, Bio-Rad Laboratories, Inc., Biocartis Group NV, bioMerieux SA, Danaher Corporation, DiaSorin S.p.A., Grifols S.A., Hologic Inc., Illumina, Inc., Johnson & Johnson, LabCorp, Myriad Genetics, Inc., Novartis AG, Roche Diagnostics Corporation, Siemens Healthineers, Sysmex Corporation by Oxford Gene Technology, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Molecular Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Technology, market is studied across Chips and Microarrays, In Situ Hybridization, Mass Spectrometry (MS), PCR, and Sequencing.
  • Based on Product, market is studied across Instruments and Reagents.
  • Based on Application, market is studied across Blood Screening, Genetic Disease Screening, Human Leukocyte Antigen Typing, Infectious Disease, Microbiology, Oncology, and Pharmacogenomics.
  • Based on End User, market is studied across Hospitals and Laboratories.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. High prevalence of infectious diseases and various types of cancers prevalence rate of hospital-acquired infections
      • 5.1.1.2. Escalation in government funding
      • 5.1.1.3. Increasing demand for point of care diagnostics
    • 5.1.2. Restraints
      • 5.1.2.1. Lack of clear and uniform regulatory framework
      • 5.1.2.2. Inefficiency of trained professionals limiting the appropriate use of new molecular diagnostic technologies
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancements in molecular diagnostics along with increasing awareness towards early disease diagnosis
      • 5.1.3.2. Rising number of R&D activities in the emerging economies
    • 5.1.4. Challenges
      • 5.1.4.1. Delay in the approval of new molecular diagnostic tests
      • 5.1.4.2. Stringent regulations associated with the approval process
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Technology: Expanding use of next-generation sequencing in personalized medicine and targeted therapies
    • 5.2.2. Applications: Integration of molecular diagnostics in precision medicine for early intervention of infectious diseases
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Molecular Diagnostics Market, by Technology

  • 6.1. Introduction
  • 6.2. Chips and Microarrays
  • 6.3. In Situ Hybridization
  • 6.4. Mass Spectrometry (MS)
  • 6.5. PCR
  • 6.6. Sequencing

7. Molecular Diagnostics Market, by Product

  • 7.1. Introduction
  • 7.2. Instruments
  • 7.3. Reagents

8. Molecular Diagnostics Market, by Application

  • 8.1. Introduction
  • 8.2. Blood Screening
  • 8.3. Genetic Disease Screening
  • 8.4. Human Leukocyte Antigen Typing
  • 8.5. Infectious Disease
  • 8.6. Microbiology
  • 8.7. Oncology
  • 8.8. Pharmacogenomics

9. Molecular Diagnostics Market, by End User

  • 9.1. Introduction
  • 9.2. Hospitals
  • 9.3. Laboratories

10. Americas Molecular Diagnostics Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Molecular Diagnostics Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Molecular Diagnostics Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Guardant Health launches Guardant360 TissueNext test with nearly 500 biomarkers
    • 13.3.2. QIAGEN and Myriad Genetics collaborate on Homologous Recombination Deficiency Test for Global Use
    • 13.3.3. Labcorp launches clinically validated ctDNA solution for early-stage colon cancer
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. ADT Biotech
  • 3. Agilent Technologies Inc.
  • 4. Becton, Dickinson, and Company
  • 5. Bio-Rad Laboratories, Inc.
  • 6. Biocartis Group NV
  • 7. bioMerieux SA
  • 8. Danaher Corporation
  • 9. DiaSorin S.p.A.
  • 10. Grifols S.A.
  • 11. Hologic Inc.
  • 12. Illumina, Inc.
  • 13. Johnson & Johnson
  • 14. LabCorp
  • 15. Myriad Genetics, Inc.
  • 16. Novartis AG
  • 17. Roche Diagnostics Corporation
  • 18. Siemens Healthineers
  • 19. Sysmex Corporation by Oxford Gene Technology
  • 20. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. MOLECULAR DIAGNOSTICS MARKET RESEARCH PROCESS
  • FIGURE 2. MOLECULAR DIAGNOSTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES MOLECULAR DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES MOLECULAR DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. MOLECULAR DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. MOLECULAR DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. MOLECULAR DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. MOLECULAR DIAGNOSTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY CHIPS AND MICROARRAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY IN SITU HYBRIDIZATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY MASS SPECTROMETRY (MS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY REAGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY BLOOD SCREENING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC DISEASE SCREENING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY HUMAN LEUKOCYTE ANTIGEN TYPING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY PHARMACOGENOMICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES MOLECULAR DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 60. AUSTRALIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 61. AUSTRALIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 64. CHINA MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 65. CHINA MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 68. INDIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 69. INDIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 72. INDONESIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. INDONESIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 76. JAPAN MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. JAPAN MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 80. MALAYSIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 81. MALAYSIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 84. PHILIPPINES MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 85. PHILIPPINES MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 88. SINGAPORE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. SINGAPORE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 92. SOUTH KOREA MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 93. SOUTH KOREA MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 96. TAIWAN MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 97. TAIWAN MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 100. THAILAND MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 101. THAILAND MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 104. VIETNAM MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 105. VIETNAM MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 113. DENMARK MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 114. DENMARK MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 117. EGYPT MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 118. EGYPT MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 121. FINLAND MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 122. FINLAND MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 125. FRANCE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 126. FRANCE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 129. GERMANY MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 130. GERMANY MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 133. ISRAEL MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 134. ISRAEL MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 137. ITALY MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 138. ITALY MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 141. NETHERLANDS MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 142. NETHERLANDS MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 145. NIGERIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 146. NIGERIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 149. NORWAY MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 150. NORWAY MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 153. POLAND MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 154. POLAND MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 157. QATAR MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 158. QATAR MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 161. RUSSIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 162. RUSSIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 165. SAUDI ARABIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 166. SAUDI ARABIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH AFRICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 170. SOUTH AFRICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 173. SPAIN MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 174. SPAIN MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 177. SWEDEN MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 178. SWEDEN MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 181. SWITZERLAND MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 182. SWITZERLAND MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 185. TURKEY MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 186. TURKEY MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED ARAB EMIRATES MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED ARAB EMIRATES MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 193. UNITED KINGDOM MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 194. UNITED KINGDOM MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 195. MOLECULAR DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 196. MOLECULAR DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023